This podcast explores how the Inflation Reduction Act’s (IRA) drug price negotiation program is reshaping the relationship between CMS, drug manufacturers, and providers. We’ll explore what the proposed IRA implementation framework means for our healthcare system, highlighting the financial, legal, and transparency implications for pharmacies and patients.
SPEAKERS
Jillanne Schulte Wall
Senior Director, Health and Regulatory Policy
ASHP
Tom Kraus
Vice President, Government Relations
ASHP
LISTEN ON
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
